ERBB2 and urothelial carcinoma: Consequently, it is imperative to elucidate the expression of HER2 protein in urothelial carcinoma and its clinicopathological correlation to facilitate the clinical application of anti-HER2 targeted therapy for this disease (Olt et al., 1990; Press et al., 1990; Mendelsohn and Baselga, 2003).